Echocardiography at pharmacological intervention protocol 6A
| Protocol 6A, day 2 . | Control . | Cfz . | Cfz+Met . | Met . |
|---|---|---|---|---|
| . | n = 8 . | n = 6 . | n = 9 . | n = 4 . |
| HR | 651.42 ± 10.07 | 648.38 ± 23.15 | 642.15 ± 12 | 647.16 ± 6.35 |
| LVEDD, mm | 3.04 ± 0.05* | 3.28 ± 0.11 | 3.18 ± 0.05 | 2.97 ± 0.11* |
| LVESD, mm | 1.61 ± 0.05****† | 1.97 ± 0.07 | 1.80 ± 0.05* | 1.63 ± 0.07*** |
| LVPWd, mm | 0.78 ± 0.01**†† | 0.73 ± 0.01 | 0.74 ± 0.01 | 0.78 ± 0.01**† |
| LVPWs, mm | 1.28 ± 0.01**†† | 1.24 ± 0.01 | 1.24 ± 0.01 | 1.29 ± 0.01**†† |
| FS, % | 46.20 ± 0.78****†† | 39.88 ± 0.20 | 43.49 ± 0.63*** | 44.94 ± 0.28**** |
| r/h | 1.98 ± 0.05* | 2.21 ± 0.09 | 2.15 ± 0.05 | 1.90 ± 0.08*† |
| Protocol 6A, day 2 . | Control . | Cfz . | Cfz+Met . | Met . |
|---|---|---|---|---|
| . | n = 8 . | n = 6 . | n = 9 . | n = 4 . |
| HR | 651.42 ± 10.07 | 648.38 ± 23.15 | 642.15 ± 12 | 647.16 ± 6.35 |
| LVEDD, mm | 3.04 ± 0.05* | 3.28 ± 0.11 | 3.18 ± 0.05 | 2.97 ± 0.11* |
| LVESD, mm | 1.61 ± 0.05****† | 1.97 ± 0.07 | 1.80 ± 0.05* | 1.63 ± 0.07*** |
| LVPWd, mm | 0.78 ± 0.01**†† | 0.73 ± 0.01 | 0.74 ± 0.01 | 0.78 ± 0.01**† |
| LVPWs, mm | 1.28 ± 0.01**†† | 1.24 ± 0.01 | 1.24 ± 0.01 | 1.29 ± 0.01**†† |
| FS, % | 46.20 ± 0.78****†† | 39.88 ± 0.20 | 43.49 ± 0.63*** | 44.94 ± 0.28**** |
| r/h | 1.98 ± 0.05* | 2.21 ± 0.09 | 2.15 ± 0.05 | 1.90 ± 0.08*† |
Echocardiographic assessment of cardiac function in protocol 6A demonstrated significant changes in all groups vs Cfz (*P < .05, ** P < .01, ***P < .001, ****P < .0001) and in the control and Met groups vs Cfz+Met group (†P < .05, ††P < .01), respectively.